Atlas Trials

Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)

Clinical trial NCT03977155 · COMPLETED

Trial details

NCT number
NCT03977155
Sponsor
Boston Pharmaceuticals
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Diarrhea-predominant Irritable Bowel Syndrome
Start date
2019-06-04
Primary completion
2020-05-06
Enrollment
133

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.